亚洲知识产权资讯网为知识产权业界提供一个一站式网上交易平台,协助业界发掘知识产权贸易商机,并与环球知识产权业界建立联系。无论你是知识产权拥有者正在出售您的知识产权,或是制造商需要购买技术以提高操作效能,又或是知识产权配套服务供应商,你将会从本网站发掘到有用的知识产权贸易资讯。

Sepsis Treatment Inactivates Endotoxins Using Molecules Derived From Chitosan Derivative

总结
Purdue University researchers have developed a novel treatment for septicemia involving molecules derived from chitosan. Chitosan is a linear carbohydrate with many commercial and biomedical uses. This treatment inactivates endotoxins, which are toxins associated with certain types of bacteria and stimulates cytokine release (part of the body's inflammatory response that causes swelling and high fever). This new chitosan shows many advantages over current IV treatments for septicemia. This technology can be used to filter endotoxins out of plasmid DNA samples and filter bacteria from water, making contaminated water samples safe to drink.
技术优势
Stronger affinity for inactivating endotoxinsExcellent biocompatibility upon injection Lower potential to cause hemolysis, complement activation, and inflammatory responsesCan filter endotoxins out of plasmid DNA samples and remove bacteria from water
技术应用
Medical/HealthSepsis treatmentContaminant removal from drinking water
详细技术说明
Yoon YeoYeo LabPurdue Industrial and Physical Pharmacy
*Abstract

*Background
Septicemia refers to the presence of pathogens in the bloodstream that leads to sepsis, a potentially life-threatening medical condition characterized by whole-body inflammation and the presence of infection. When microbes infect the blood, skin, lungs or other tissues, the body's immune system generates an inflammatory response in an attempt to fight the infection. The body's immune response to the infection causes the characteristic symptoms of sepsis and can lead to organ failure. The current treatment for sepsis requires antibiotics, fluid drainage, blood transfusions, and dialysis. Since individual cases are caused by different microbes, the correct antibiotic must be chosen to treat the infection. This causes a delay in treatment, which leads to an increase in the mortality rate.
*IP Issue Date
None
*IP Type
Utility
*Stage of Development
Proof of Concept
*Web Links
Purdue Office of Technology CommercializationPurdueInnovation and EntrepreneurshipYoon YeoYeo LabPurdue Industrial and Physical Pharmacy
国家
United States
申请号码
None
国家/地区
美国

欲了解更多信息,请点击 这里
移动设备